Inhibiting SGLT2 by Gliflozins greatly reduced tumor growth and prolonged survival in mouse models, suggesting that SGLT2 is a potential diagnostic and therapeutic target for early-stage LUAD [6]. The gene discussed is SLC5A2; the disease is neoplasm.